Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (211-220 of 327) with videos related to

Pageof 33
Sort By:
Circulation|October 2, 2020
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic PlaqueZsofia D Drobni, Raza M Alvi, Jana Taron, et al.
Cancer|June 23, 2020
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitisShilpa Grover, Michael Dougan, Kevin Tyan, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.
JACC. Cardiooncology|January 13, 2023
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After ImmunotherapyCharlotte Lee, Zsofia D Drobni, Amna Zafar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaRachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Pageof 33

Showing results (211-220 of 327) with videos related to

Sort By:
Pageof 33
Circulation|October 2, 2020
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic PlaqueZsofia D Drobni, Raza M Alvi, Jana Taron, et al.
Cancer|June 23, 2020
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitisShilpa Grover, Michael Dougan, Kevin Tyan, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.
JACC. Cardiooncology|January 13, 2023
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After ImmunotherapyCharlotte Lee, Zsofia D Drobni, Amna Zafar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaRachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Pageof 33